GLUE — Monte Rosa Therapeutics
Median target
$27
calls from the last 12 months
Implied return
+159.4%
median target vs. price
Coverage
7 analysts · 8 calls
updated in the last 12 months
Consensus
7/0/0+7 net
Buy / Hold / Sell
Which analysts are behind GLUE's consensus?
See every current rating, price target and the analysts' track records for Monte Rosa Therapeutics — plus the full analyst rankings, firm analytics and screener.
The consensus above reflects 7 analysts with calls on GLUE updated in the last 12 months. Implied return is the move implied if the consensus target were hit. These are forward-looking predictions, not realized returns. Per-analyst ratings and track records are a Premium feature.
GLUE elsewhere on AnalystEdge
The most recent congressional, executive-branch and insider filings matched to this ticker. Matched by ticker symbol — occasional mismatches are possible. Not investment advice.
Trending today: not in any of today's trending tables (Gaining attention, Losing attention, Most followed)
| Date | Source | Who | Action | Detail | Amount |
|---|---|---|---|---|---|
| 2026-10-05 | Insiders | Bowen MatthewPrincipal Accounting Off | Insider sale | 13 sh @ $10.56 | $137 |
More: insider activity · executive branch · trending